Cirrhosis is one of the common and frequent diseases in China, and ruptured esophageal variceal bleeding is the most common and serious complication of portal hypertension in cirrhosis. How to prevent upper gastrointestinal bleeding and improve the survival rate of patients with cirrhosis is an important clinical issue. The traditional surgical shunt is effective in reducing the effect of portal pressure, but the postoperative liver blood supply is reduced and the incidence of hepatic encephalopathy is high. Although the dissection ensures the blood supply to the liver, the postoperative in bleeding rate is high and the long-term survival rate is not satisfactory. According to the increased venous blood flow and increased intrahepatic portal vascular resistance is the pathophysiological basis for the occurrence of portal hypertension in cirrhosis. For its pathogenesis, the drugs currently used clinically for the treatment of portal hypertension have been vasoconstrictive drugs such as: insulin, aminocardium, cardiac pain, cardiac pain, etc.; other drugs such as diuretics, gastroprokinetic drugs, Chinese herbal medicine, etc. to prevent the occurrence of upper gastrointestinal bleeding for the first time or again. However, there is no drug that can effectively reduce both portal pressure and anti-hepatic fibrosis effect, and does not cause changes in liver function, renal function and systemic hemodynamics. Valsartan acting on hepatic stellate cells can safely and effectively reduce portal pressure in cirrhosis and exert anti-fibrotic effects, without significant effects on systemic hemodynamics.